Mineralys Therapeutics, Inc. (MLYS)

Mineralys Therapeutics' stock price has been influenced by several events over the past six months. In March 2025, shares rallied 42% following positive data from clinical trials for lorundrostat, and the company announced an underwritten public offering at $13.50 per share. In June 2025, positive topline results were announced from the Phase 2 Explore-CKD trial. In August 2025, the company reported its second-quarter financial results and highlighted positive results from three clinical trials. In September 2025, Mineralys announced an upsized underwritten public offering at $25.50 per share and completed enrollment in its Phase 2 EXPLORE-OSA trial. In October 2025, the stock reached its all-time high of $44.80 USD, and the company announced a late-breaking presentation of Phase 2 Explore-CKD trial data at the American Society of Nephrology (ASN) Kidney Week 2025.

As a clinical-stage biopharmaceutical company without commercialized products, Mineralys Therapeutics, Inc. does not have traditional demand seasonality. Demand will emerge upon regulatory approval and commercial launch of lorundrostat.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for diseases driven by abnormally elevated aldosterone, operating within the Healthcare sector and Biotechnology industry. The company's primary product candidate is lorundrostat, an orally administered aldosterone synthase inhibitor, being developed for hypertension, chronic kidney disease, and obstructive sleep apnea. The company aims to provide targeted treatments for hypertension and related cardiorenal diseases and was incorporated in 2019, with its headquarters in Radnor, Pennsylvania.

Mineralys Therapeutics, Inc. is headquartered in Radnor, Pennsylvania, United States. The company's clinical development and focus on developing medicines are primarily within the United States.

Mineralys Therapeutics has maintained a positive brand reputation over the past year, driven by successful clinical trial results and presentations. Positive outcomes from the Launch-HTN, Advance-HTN, and Explore-CKD trials have bolstered the company's standing. The company's commitment to developing targeted treatments for diseases driven by elevated aldosterone has been consistently highlighted. There have been no reported events that have negatively impacted Mineralys Therapeutics, Inc.'s reputation in the past year.

As of September 2025, two institutions reported a stake in Mineralys Therapeutics, Inc., with GAMMA Investing LLC and Rise Advisors, LLC as leading institutional holders. As of June 30, 2025, major institutional owners included Catalys Pacific, LLC, RA CAPITAL MANAGEMENT, L.P., Samsara BioCapital, LLC, SR ONE CAPITAL MANAGEMENT, LP, BlackRock, Inc., and Capital International Investors. As of June 17, 2025, institutional ownership stood at 96.8%, while insider ownership was 1.88%.